




英文版仅为中文版之翻译，若中英歧义，请以中文版为准。

The English translation is for reference purposes only.

In the event of any discrepancy between the Chinese original and the English translation,
the Chinese original shall prevail.

2025 第一季度报告

The First Quarter Report in 2025



甘李药业股份有限公司

GAN & LEE PHARMACEUTICALS.

股票代码：603087

STOCK CODE: 603087

目 录

Contents

重要内容提示 Important Notes	3
一、主要财务数据 I Major Financial Data	4
二、股东信息 II Shareholder Information	10
三、季度财务报表 III Quarterly Financial Statements	15

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。

The Board of Directors and all Company directors warrant that there are no false records, misleading statements, or material omissions in this announcement. They are legally responsible for the truthfulness, accuracy, and completeness of its contents.

重要内容提示：

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。

公司负责人甘忠如、主管会计工作负责人孙程及会计机构负责人(会计主管人员)周丽保证季度报告中财务信息的真实、准确、完整。

第一季度财务报表是否经审计

否

Important Notes

The Board of Directors, the Supervisory Committee and directors, supervisors, and senior management of the Company guarantee the truthfulness, accuracy and completeness of the contents of the quarterly report, and that there are no false records, misleading statements or material omissions, for which they shall be individually and jointly liable.


The legal representative is Zhongru Gan, the chief accountant is Cheng Sun and head of accounting department (accounting supervisor) is Li Zhou certify that the financial report set out in the quarterly report is true, accurate and complete.

Whether the first quarter financial statements are audited

No

主要财务数据

Major Financial Data



一、主要财务数据

I Major Financial Data

(一) 主要会计数据和财务指标

(I) Major accounting data and financial indicators

单位：元 币种：人民币
Unit: RMB

项目 Item	本报告期 Current reporting period	上年同期 Same period of the previous year	本报告期比上年同期增减变 动幅度(%) Increase/decrease during the reporting period over the same period of the previous year (%)
营业收入 Operating income	984,867,402.61	560,334,209.70	75.76
归属于上市公司股东的净利润 Net profit attributable to shareholders of the listed company	311,918,723.02	96,004,278.20	224.90
归属于上市公司股东的扣除非经常性损益的净利润 Net profit attributable to shareholders of the listed company after the deduction of non-recurring gains and losses	214,645,947.22	17,169,319.18	1,150.17
经营活动产生的现金流量净额 Net cash flows from operating activities	158,746,266.77	81,288,354.73	95.29
基本每股收益(元/股) Basic earnings per share (RMB per share)	0.53	0.16	231.25
稀释每股收益(元/股) Diluted earnings per share (RMB per share)	0.53	0.16	231.25
加权平均净资产收益率(%) Weighted average return on net assets (%)	2.78	0.89	增加1.89个百分点 Increase by 1.89 percentage points
	本报告期末 End of the current reporting period	上年度末 End of the previous year	本报告期末比上年度末增减 变动幅度(%) Change in the current reporting period over the end of the previous year (%)
总资产 Total assets	12,284,434,818.79	12,042,916,391.88	2.01
归属于上市公司股东的所有者权益 Owners' equity attributable to shareholders of listed company	11,312,123,449.60	11,054,470,662.18	2.33

注：“本报告期”指本季度初至本季度末3个月期间，下同。

Note: "Current reporting period" refers to the three-month period from beginning to end of the current quarter, and the same applies hereinafter.

(二) 非经常性损益项目和金额

(II) Items and amounts of non-recurring gains and losses

单位: 元 币种: 人民币
Unit: RMB

非经常性损益项目	Items of non-recurring gains and losses	本期金额 Amount for the current reporting period	说明 Note
非流动性资产处置损益, 包括已计提资产减值准备的冲销部分	Gains and losses on disposal of non-current assets, including the reversal of previously recognized asset impairment provisions	-108,285.52	
计入当期损益的政府补助, 但与公司正常经营业务密切相关、符合国家政策规定、按照确定的标准享有、对公司损益产生持续影响的政府补助除外	Government grants recognized in profit or loss for the current period, excluding those closely related to the Company's business, in compliance with national policy regulations, received according to established criteria, and having a continuous impact on the Company's profit or loss	2,717,784.43	
除同公司正常经营业务相关的有效套期保值业务外, 非金融企业持有金融资产和金融负债产生的公允价值变动损益以及处置金融资产和金融负债产生的损益	Gains and losses from changes in the fair value of financial assets and liabilities held by non-financial corporations, and gains and losses from the disposal of financial assets and liabilities, except for effective hedging operations related to the Company's normal business operations	50,657,973.75	
除上述各项之外的其他营业外收入和支出	Non-operating income and expenses other than those listed above	61,213,811.83	主要系收到通化东宝药业股份有限公司诉讼执行款。 Mainly due to the receipt of litigation execution funds from Tonghua Dongbao Pharmaceutical Co., Ltd.
其他符合非经常性损益定义的损益项目	Other items of profit or loss that meet the definition of non-recurring gains and losses	14,584.26	
减: 所得税影响额	Less: Amount affected by income tax	17,223,092.95	
少数股东权益影响额(税后)	Effect of minority interests (after tax)		
合计	Total	97,272,775.80	

对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非经常性损益项目且金额重大的, 以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目, 应说明原因。

For items of non-recurring gains and losses that the Company has recognized as items of non-recurring gains and losses not listed in "Interpretative Announcement for Information Disclosure of Companies Issuing Securities No.1 - Non-recurring Gains and Losses" and the amount of which is material, as well as items defined as non-recurring gains and losses in "Interpretative Announcement for Information Disclosure of Companies Issuing Securities No.1 - Non-recurring Gains and Losses", the reasons shall be explained.

单位：元 币种：人民币
Unit: RMB

项目名称 Item	涉及金额 Amount	原因 Reason
递延收益的摊销 Amortization of deferred income	2,294,041.99	本公司将资产相关的政府补助递延收益的摊销认定为经常性损益。 The Company recognizes the amortization of deferred income from asset-related government grants as recurring gains and losses.

(三) 主要会计数据、财务指标发生变动的情况、原因 (III) Changes in major accounting data and financial indicators, and the reasons therefor

项目名称 Item	变动比例(%) Percentage of change (%)	主要原因 Main Reason
营业收入 Operating income	75.76	见表格下方。 See note below the table.
归属于上市公司股东的净利润 Net profit attributable to shareholders of listed companies	224.90	主要得益于报告期内营业收入的增加。 Mainly due to the increase in operating income during the current reporting period.
归属于上市公司股东的扣除非经常性损益的净利润 Net profit attributable to shareholders of listed companies after deduction of non-recurring profits or losses	1,150.17	同上。 As above.
经营活动产生的现金流量净额 Net cash flows from operating activities	95.29	主要系报告期内销售商品收到的现金增加。 Mainly due to the increase in cash received from the sale of goods.
基本每股收益 Basic earnings per share	231.25	主要系本报告期归属于上市公司股东的净利润同比增加。 Mainly due to the increase in net profit attributable to shareholders of the listed company.
稀释每股收益 Diluted earnings per share	231.25	主要系本报告期归属于上市公司股东的净利润同比增加所致。 Mainly due to the increase in net profit attributable to shareholders of the listed company for the reporting period.

营业收入变动原因：

2025年第一季度，营业收入为9.85亿元，与上年同期相比增加4.25亿元，同比增长75.76%。公司国内外收入均实现大幅增长，具体情况如下：

The reasons for the changes in operating income:

In the first quarter of 2025, operating income was RMB 985 million, an increase of RMB 425 million compared to the same period last year. The company has achieved substantial growth in both domestic and foreign revenues. The specific situation is as follows:

营业收入分地区情况

Operating income by region

单位：亿元

Unit: RMB 100 million

分地区 By region	2025年第一季度 Operating income for the first quarter of 2025		
	金额 Amount	同期变动额 Change amount for the same period	同期变动率 Change rate for the same period
国内销售收入 Domestic sales revenue	8.89	3.95	80.07%
国际销售收入 International sales revenue	0.95	0.30	45.21%
国际特许权服务收入 International franchise service income	0.004	-0.005	-58.64%
营业收入合计 Total operating income	9.85	4.25	75.76%

注释：表中数据尾差是由于四舍五入所致


Note: The discrepancies in the table data are due to rounding.

(1) 国内销售收入保持强劲增长。2025年第一季度，国内销售收入为8.89亿元，较上年同期增加3.95亿元，同比增长80.07%，主要系国内胰岛素制剂产品销量较上年同期大幅增长。2024年，公司积极参加了国家胰岛素专项接续集采的投标工作，并取得了积极的成果。本次胰岛素接续集采的采购周期从首次集采的两年延长至三年半(2024年5月至2027年12月)。在新一轮集采中选结果落地执行的红利下，公司国内胰岛素制剂产品2025年一季度销售收入8.64亿元，同比增长80.93%。其中，公司基础(长效)胰岛素产品销售收入5.43亿元，同比增长80.97%；公司餐时(速效)和预混胰岛素产品销售收入3.21亿元，同比增长80.86%。本报告期内，国内胰岛素制剂产品销量与价格增长效应协同显现，为收入增长提供了有力支撑，销量影响和价格影响分别为2.38亿元、1.48亿元，详见图1。

(1) Domestic sales revenue maintained strong growth. In the first quarter of 2025, domestic sales revenue amounted to RMB 889 million, representing an increase of RMB 395 million, or 80.07% year-on-year, compared with the same period of the previous year, which was mainly due to the substantial increase in sales of domestic insulin preparation products compared with the same period of the previous year. In 2024, the Company actively participated in the bidding for the national insulin-specific successive VBP and achieved positive results. The procurement cycle of this insulin-specific successive VBP was extended to three and a half years(from May 2024 to December 2027) from two years of the first round of VBP. Under the favorable impact of the successful results of the new round of VBP landing implementation, the Company's domestic insulin preparation products sales revenue of RMB 864 million in the first quarter of 2025, an increase of 80.93% year-on-year. Among them, the sales revenue of the Company's basal (long-acting) insulin products amounted to RMB 543 million, representing a year-on-year growth of 80.97%; the sales revenue of the Company's mealtime (rapid-acting) and premixed insulin products amounted to RMB 321 million, representing a year-on-year growth of 80.86%. During the reporting period, the synergistic effect of sales volume and price growth of domestic insulin preparation products was evident, which provided strong support for the revenue growth, with sales volume impact and price impact amounting to RMB 238 million and RMB 148 million respectively, as shown in Figure 1.

图1：国内制剂收入变动因素分析

Figure 1: Analysis of factors influencing domestic preparation revenue changes



注释：销量影响 = (2025年1-3月销售量 - 2024年1-3月销售量) * 2024年1-3月平均单价；价格影响 = (2025年1-3月平均价格 - 2024年1-3月平均价格) * 2025年1-3月销售量。

Note: Sales volume impact = (Sales volume of Jan.to Mar. in 2025 - Sales volume of Jan.to Mar.in 2024) * Average unit price of Jan.to Mar. in 2024


Price impact = (Average unit price of Jan.to Mar. in 2025 - Average unit price of Jan.to Mar. in 2024) * Sales volume of Jan.to Mar.in 2025

(2) 出口业务收入持续攀升。报告期内，公司依然稳步推进国际市场开拓工作，得益于新兴市场的深度开拓与核心产品竞争力的持续提升。2025年第一季度，国际销售订单量持续增加，国际销售收入为0.95亿元，较上年同期增长45.21%。未来，公司将继续深化全球化布局，以创新驱动出口业务迈向更高增长曲线。

(2) Revenue from export business continued to climb. During the reporting period, the Company still steadily pushed forward the development of the international market, thanks to the depth of development of emerging markets and the continuous improvement of the competitiveness of core products. In the first quarter of 2025, the volume of international sales orders continued to increase, and the revenue from international sales amounted to RMB 95 million, an increase of 45.21% compared with the same period of the previous year. In the future, the Company will continue to deepen the globalization layout and drive the export business towards a higher growth curve with innovation.

股东信息

Shareholder Information



二、股东信息

II Shareholder Information

(一) 普通股股东总数和表决权恢复的优先股股东数 (I) Total number of ordinary shareholders, the number of preferred shareholders with voting rights restored, and the top ten shareholders' shareholding

单位：股
Unit: Share

报告期末普通股股东总数	74,987	报告期末表决权恢复的优先股股东总数(如有)	0			
Total number of ordinary shareholders at the end of the current reporting period	74,987	Total number of preferred shareholders with voting rights restored at the end of the current reporting period (if any)	0			
前10名股东持股情况(不含通过转融通出借股份)						
Shareholdings of top ten shareholders (excluding lending of shares through a swap)						
股东名称	Shareholder name	持股数量	持股比例(%)	持有有限售条件股份数量	质押、标记或冻结情况	
		Number of shares held	Shareholding ratio (%)	Number of restricted shares held	Status of shares pledged, tagged, or frozen	
股份状态	Share status	数量			数量	
		Number			Number	
甘忠如	Zhongru Gan	205,643,757	34.21	28,508,550	质押	28,210,000
					Pledged	
北京旭特宏达科技有限公司	Beijing Xute Hongda Technology Co., Ltd.	41,483,857	6.90		质押	10,900,000
					Pledged	
香港中央结算有限公司	Hong Kong Securities Clearing Company Limited	7,335,122	1.22		无	
					None	
甘喜茹	Xiru Gan	6,223,276	1.04		无	
					None	
明华创新技术投资(香港)有限公司	MING HUA TECHNOLOGY INVESTMENT (HK) LIMITED	6,076,162	1.01		无	
					None	
中国银行股份有限公司—招商国证生物医药指数分级证券投资基金	Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	6,044,200	1.01		无	
					None	

单位：股
Unit: Share

前10名股东持股情况(不含通过转融通出借股份)									
Shareholder name	Shareholder name	Nature of shareholders	Number of shares held	Shareholding ratio (%)	Number of restricted shares held	Share status	Status of shares pledged, tagged, or frozen	Number	Number
股东名称	Shareholder name	股东性质	持股数量	持股比例(%)	持有有限售条件股份数量	质押、标记或冻结情况	股份状态	数量	数量
中国农业银行股份有限公司－中证500交易型开放式指数证券投资基金	Agricultural Bank of China Limited - CSI 500 Exchange Traded Open-End Index Securities Investment Fund	其他 Other	4,676,008	0.78		无 None			
Hillhouse G&L Holdings (HK) Limited	Hillhouse G&L Holdings (HK) Limited	境外法人 Overseas legal entity	4,296,032	0.71	4,296,032	无 None			
STRONG LINK INTERNATIONAL LIMITED	STRONG LINK INTERNATIONAL LIMITED	国有法人 State-owned legal entity	4,256,033	0.71	4,256,033	无 None			
张加珍	Jiazhen Zhang	境内自然人 Domestic natural person	4,213,300	0.70		无 None			

单位：股
Unit: Share

前10名无限售条件股东持股情况(不含通过转融通出借股份)				持有无限售条件流通股的数量	股份种类	股份种类及数量
Shareholdings of top ten shareholders (excluding lending of shares through a swap)				Number of unlimited shares outstanding	Category	Category and number of shares
股东名称	Shareholder name					数量 Number
甘忠如	Zhongru Gan			177,135,207	人民币普通股 RMB ordinary shares	177,135,207
北京旭特宏达科技有限公司	Beijing Xute Hongda Technology Co.,Ltd			41,483,857	人民币普通股 RMB ordinary shares	41,483,857
香港中央结算有限公司	Hong Kong Securities Clearing Company Limited			7,335,122	人民币普通股 RMB ordinary shares	7,335,122
甘喜茹	Xiru Gan			6,223,276	人民币普通股 RMB ordinary shares	6,223,276
明华创新技术投资(香港)有限公司	MING HUA TECHNOLOGY INVESTMENT (HK) LIMITED			6,076,162	人民币普通股 RMB ordinary shares	6,076,162
中国银行股份有限公司—招商国证生物医药指数分级证券投资基金	Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund			6,044,200	人民币普通股 RMB ordinary shares	6,044,200
中国农业银行股份有限公司—中证500交易型开放式指数证券投资基金	Agricultural Bank of China Limited - CSI 500 Exchange Traded Open-End Index Securities Investment Fund			4,676,008	人民币普通股 RMB ordinary shares	4,676,008
张加珍	Jiazhen Zhang			4,213,300	人民币普通股 RMB ordinary shares	4,213,300
中国人寿保险股份有限公司—传统—普通保险产品—005L—CT001沪	China Life Insurance Company Limited - Traditional - Ordinary Insurance Product - 005L - CT001 Shanghai			3,961,003	人民币普通股 RMB ordinary shares	3,961,003
中国建设银行股份有限公司—华安聚优精选混合型证券投资基金	China Construction Bank Corporation - Hua An Joyous Selection Mixed Securities Investment Fund			3,378,318	人民币普通股 RMB ordinary shares	3,378,318
上述股东关联关系或一致行动的说明	Explanation of the above shareholders' affiliation or concerted action					
前10名股东及前10名无限售股东参与融资融券及转融通业务情况说明(如有)	Explanation on the participation of the top ten shareholders and the top ten unlimited shareholders in the margin financing and lending of shares in the transfer and refinancing business (if any)					
						公司控股股东、实际控制人甘忠如持有旭特宏达65.02%的股权；甘喜茹为甘忠如胞妹。除以上情况外，其他股东之间不存在关联关系或一致行动。 Zhongru Gan, the controlling shareholder and actual controller of the Company, holds 65.02% of the shares of Beijing Xute Hongda Technology Co.,Ltd. Xiru Gan is the sibling of Zhongru Gan. Apart from the above, there is no affiliation or concerted action among other shareholders.
						不适用 N/A

持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况

Participation of shareholders holding 5% or more of shares, the top 10 shareholders, and the top 10 shareholders with unlimited shares in circulation in lending of shares in the transfer and refinancing business

单位：股
Unit: Share

持股5%以上股东及前10名无限售流通股股东参与转融通业务出借股份情况	持股5%以上股东及前10名无限售流通股股东参与转融通业务出借股份情况	持股5%以上股东及前10名无限售流通股股东参与转融通业务出借股份情况	持股5%以上股东及前10名无限售流通股股东参与转融通业务出借股份情况	持股5%以上股东及前10名无限售流通股股东参与转融通业务出借股份情况	持股5%以上股东及前10名无限售流通股股东参与转融通业务出借股份情况
Participation of shareholders holding 5% or more of shares, the top 10 shareholders, and the top 10 shareholders with unlimited shares in circulation in lending of shares in the transfer and refinancing business	Participation of shareholders holding 5% or more of shares, the top 10 shareholders, and the top 10 shareholders with unlimited shares in circulation in lending of shares in the transfer and refinancing business	Participation of shareholders holding 5% or more of shares, the top 10 shareholders, and the top 10 shareholders with unlimited shares in circulation in lending of shares in the transfer and refinancing business	Participation of shareholders holding 5% or more of shares, the top 10 shareholders, and the top 10 shareholders with unlimited shares in circulation in lending of shares in the transfer and refinancing business	Participation of shareholders holding 5% or more of shares, the top 10 shareholders, and the top 10 shareholders with unlimited shares in circulation in lending of shares in the transfer and refinancing business	Participation of shareholders holding 5% or more of shares, the top 10 shareholders, and the top 10 shareholders with unlimited shares in circulation in lending of shares in the transfer and refinancing business
股东名称	Shareholder name	期初普通账户、信用账户持股数量合计	期初普通账户、信用账户持股比例(%)	期初转融通出借股份且尚未归还数量合计	期初转融通出借股份且尚未归还比例(%)
		General and credit account holdings at the beginning of the current period	Proportion (%)	Shares lent in the transfer and refinancing business and has not yet been returned at the beginning of the current period	Proportion (%)
		数量合计	比例(%)	数量合计	比例(%)
		Total quantity	Proportion (%)	Total quantity	Proportion (%)
中国银行股份有限公司－招商国证生物医药指数分级证券投资基金	Bank of China Limited - China Merchants CSI Biomedical Index Split-level Securities Investment Fund	6,228,400	1.04	0	0
合计	Total	6,228,400	1.04	0	0

季度财务报表

Quarterly Financial Statements



三、季度财务报表

III Quarterly Financial Statements

(一) 财务报表

(I) Financial statements

合并资产负债表
Consolidated statement of financial position2025年3月31日
March 31, 2025编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2025年3月31日 March 31, 2025	2024年12月31日 December 31, 2024
流动资产:	Current Assets:		
货币资金	Cash and Cash equivalents	1,058,837,161.68	902,777,760.68
交易性金融资产	Financial assets held for trading	1,297,700,883.56	1,500,496,835.63
应收票据	Notes receivable	6,091,659.92	12,246,237.38
应收账款	Accounts receivable	328,247,465.16	213,714,496.82
应收款项融资	Financing receivables	5,147,466.99	20,758,005.45
预付款项	Prepayments	51,527,747.22	56,562,468.46
其他应收款	Other receivables	3,108,901.33	1,847,488.41
存货	Inventories	1,113,062,811.37	1,052,906,832.75
一年内到期的非流动资产	Non-current assets due within one year	5,816,625.61	5,089,557.41
其他流动资产	Other current assets	30,732,217.91	24,458,526.06
流动资产合计	Total current assets	3,900,272,940.75	3,790,858,209.05
非流动资产:	Non-current Assets:		
债权投资	Debt investment	500,693,245.81	497,027,269.78
长期应收款	Long-term receivables	7,025,028.27	7,669,407.96
其他非流动金融资产	Other non-current financial assets	46,500,132.70	11,713,152.96
固定资产	Fixed assets	2,620,823,241.17	2,615,687,526.41
在建工程	Construction in progress	1,253,137,910.49	1,262,027,468.83
使用权资产	Right-of-use assets	3,977,149.53	4,323,594.06
无形资产	Intangible assets	266,659,170.69	273,059,639.42
开发支出	Development expenditures	1,045,134,396.87	917,812,401.72
长期待摊费用	Long-term deferred expenses	6,658,839.21	7,101,160.03
递延所得税资产	Deferred tax assets	213,850,575.46	206,935,277.52
其他非流动资产	Other non-current assets	2,419,702,187.84	2,448,701,284.14
非流动资产合计	Total non-current assets	8,384,161,878.04	8,252,058,182.83
资产总计	Total assets	12,284,434,818.79	12,042,916,391.88
流动负债:	Current Liabilities		
应付账款	Accounts payable	112,916,647.49	129,129,386.84
合同负债	Contract liabilities	54,027,662.66	63,254,168.23

合并资产负债表 (续)
Consolidated statement of financial position (Continued)

项目	Item	2025年3月31日 March 31, 2025	2024年12月31日 December 31, 2024
应付职工薪酬	Payroll and employee benefits payable	167,434,441.77	150,681,683.52
应交税费	Taxes payable	11,840,226.55	11,191,413.07
其他应付款	Other payables	431,848,339.35	426,587,948.23
一年内到期的非流动负债	Non-current liabilities due within one year	8,399,982.16	10,056,983.05
其他流动负债	Other current liabilities	6,747,296.88	10,230,151.30
流动负债合计	Total current liabilities	793,214,596.86	801,131,734.24
非流动负债：	Non-current Liabilities:		
租赁负债	Lease liabilities	3,056,451.84	3,306,003.23
长期应付款	Long-term payable	2,646,761.09	2,973,351.09
递延收益	Deferred income	168,829,847.63	168,923,889.62
递延所得税负债	Deferred tax liabilities	4,563,711.77	12,110,751.52
非流动负债合计	Total non-current liabilities	179,096,772.33	187,313,995.46
负债合计	Total liabilities	972,311,369.19	988,445,729.70
所有者权益(或股东权益)：	Owners' (or Shareholders') equity:		
实收资本(或股本)	Paid-in capital (or share capital)	601,065,290.00	601,065,290.00
资本公积	Capital reserve	3,611,154,661.55	3,590,961,537.76
减：库存股	Less: Treasury share	275,644,784.92	200,846,739.31
其他综合收益	Other comprehensive income	4,375,941.88	4,036,955.66
盈余公积	Surplus reserve	300,532,645.00	300,532,645.00
未分配利润	Retained earnings	7,070,639,696.09	6,758,720,973.07
归属于母公司所有者权益(或股东权益)合计	Total owner's equity (or shareholders' equity) attributable to the parent company	11,312,123,449.60	11,054,470,662.18
少数股东权益	Non-controlling interests		
所有者权益(或股东权益)合计	Total owners' (or shareholders') equity	11,312,123,449.60	11,054,470,662.18
负债和所有者权益(或股东权益)总计	Total liabilities and owners' (or Shareholders') equity	12,284,434,818.79	12,042,916,391.88

公司负责人：	甘忠如	主管会计工作负责人：	孙程	会计机构负责人：	周丽
Legal Representative:	Zhongru Gan	Chief Accountant:	Cheng Sun	Head of Accounting Department:	Li Zhou

合并利润表

Consolidated Income Statement

2025年1—3月
Jan. to Mar., 2025编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2025年第一季度 First quarter of 2025	2024年第一季度 First quarter of 2024
一、营业总收入	I. Total Revenue	984,867,402.61	560,334,209.70
其中:营业收入	Of which: Operating income	984,867,402.61	560,334,209.70
二、营业总成本	II. Total operating costs	739,374,819.17	541,954,966.18
其中:营业成本	Of which: Operating costs	228,909,866.25	152,249,465.95
税金及附加	Taxes and surcharges	9,066,767.40	6,264,933.61
销售费用	Selling expenses	326,526,305.76	227,086,625.00
管理费用	General and administrative expenses	69,653,246.71	43,299,233.12
研发费用	R&D expenses	130,445,929.06	133,120,155.74
财务费用	Financial expenses	-25,227,296.01	-20,065,447.24
加:其他收益	Add: Other income	5,061,170.15	6,339,484.78
投资收益(损失以“-”号填列)	Investment income or loss (loss is indicated with "-")	3,388,058.82	2,265,318.10
公允价值变动收益(损失以“-”号填列)	Gain or loss on the changes in fair value (loss is indicated with "-")	46,991,997.72	85,501,251.91
信用减值损失(损失以“-”号填列)	Credit impairment losses (loss is indicated with "-")	-1,891,609.87	
资产减值损失(损失以“-”号填列)	Assets impairment losses (loss is indicated with "-")		49,622.31
资产处置收益(损失以“-”号填列)	Gain or loss from disposal of assets (loss is indicated with "-")		580,914.39
三、营业利润(亏损以“-”号填列)	III. Operating Profit (loss is indicated with "-")	299,042,200.26	113,115,835.01
加:营业外收入	Add: Non-operating income	61,874,025.33	519,781.04
减:营业外支出	Less: Non-operating expenses	525,341.28	75,272.07
四、利润总额(亏损总额以“-”号填列)	IV. Profit before tax (loss is indicated with "-")	360,390,884.31	113,560,343.98
减:所得税费用	Less: Income tax expense	48,472,161.29	17,556,110.25
五、净利润(净亏损以“-”号填列)	V. Net Profit (loss is indicated with "-")	311,918,723.02	96,004,233.73
(一)按经营持续性分类	(I) Categorized by operation continuity		
1.持续经营净利润(净亏损以“-”号填列)	1. Net profit from continuing operations (loss is indicated with "-")	311,918,723.02	96,004,233.73

合并利润表 (续)
Consolidated Income Statement (Continued)

项目	Item	2025年第一季度 First quarter of 2025	2024年第一季度 First quarter of 2024
(二) 按所有权归属分类	(II) Categorized by ownership		
1. 归属于母公司股东的净利润(净亏损以“-”号填列)	1. Net profit attributable to owners of the parent (net loss is indicated with "-")	311,918,723.02	96,004,278.20
2. 少数股东损益(净亏损以“-”号填列)	2. Net profit attributable to non-controlling interests (net loss is indicated with "-")		-44.47
六、其他综合收益的税后净额	VI. Other comprehensive income net of tax	338,986.22	-110,985.06
(一) 归属母公司所有者的其他综合收益的税后净额	(I) Other comprehensive income, net of tax, attributable to owners of the parent company	338,986.22	-110,985.06
1. 不能重分类进损益的其他综合收益	1. Other comprehensive income cannot be reclassified to profit or loss		
2. 将重分类进损益的其他综合收益	2. Other comprehensive income to be reclassified to profit or loss	338,986.22	-110,985.06
(1) 外币财务报表折算差额	(1) Exchange differences on translation of foreign currency financial statements	338,986.22	-110,985.06
(二) 归属于少数股东的其他综合收益的税后净额	(II) Other comprehensive income net of tax attributable to non-controlling interests		
七、综合收益总额	VII. Total Comprehensive Income	312,257,709.24	95,893,248.67
(一) 归属于母公司所有者的综合收益总额	(I) Total comprehensive income attributable to owners of the parent company	312,257,709.24	95,893,293.14
(二) 归属于少数股东的综合收益总额	(II) Total comprehensive income attributable to non-controlling interests		-44.47
八、每股收益：	VIII. Earnings Per Share:		
(一) 基本每股收益(元/股)	(I) Basic earnings per share (RMB per share)	0.53	0.16
(二) 稀释每股收益(元/股)	(II) Diluted earnings per share (RMB per share)	0.53	0.16

本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0元，上期被合并方实现的净利润为：0元。

As for a business combination under the same control in the current period, the net profit generated by the merged party before the combination was RMB 0, and that generated during the previous period was RMB 0.

公司负责人：	甘忠如	主管会计工作负责人：	孙程	会计机构负责人：	周丽
Legal Representative:	Zhongru Gan	Chief Accountant:	Cheng Sun	Head of Accounting Department:	Li Zhou

合并现金流量表

Consolidated Statement of Cash Flows

2025年1—3月
Jan. to Mar., 2025

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2025年第一季度 First quarter of 2025	2024年第一季度 First quarter of 2024
一、经营活动产生的现金流量: I. Cash Flows from Operating Activities:			
销售商品、提供劳务收到的现金	Cash receipts from the sale of goods and the rendering of services	908,976,184.90	648,170,407.38
收到的税费返还	Tax refunds received	40,666,316.18	35,184,163.91
收到其他与经营活动有关的现金	Cash received relating to other operating activities	67,079,616.13	5,344,312.42
经营活动现金流入小计	Sub-total of cash inflows from operating activities	1,016,722,117.21	688,698,883.71
购买商品、接受劳务支付的现金	Cash paid for purchase of goods and services	261,817,120.26	167,310,878.41
支付给职工及为职工支付的现金	Cash paid to and on behalf of employees	244,825,723.94	206,967,260.27
支付的各项税费	Cash paid for taxes	103,046,569.52	28,622,858.18
支付其他与经营活动有关的现金	Cash paid relating to other operating activities	248,286,436.72	204,509,532.12
经营活动现金流出小计	Sub-total of cash outflows from operating activities	857,975,850.44	607,410,528.98
经营活动产生的现金流量净额	Net cash flows from operating activities	158,746,266.77	81,288,354.73
二、投资活动产生的现金流量: II. Cash Flows from Investing Activities:			
收回投资收到的现金	Cash received from recovery of investments	2,022,569,770.00	2,304,749,855.11
取得投资收益收到的现金	Cash receipts from investment income	34,674,396.05	22,772,877.41
处置固定资产、无形资产和其他长期资产收回的现金净额	Net proceeds from disposal of fixed assets, intangible assets, and other long-term assets	819,494.19	1,413,211.03
收到其他与投资活动有关的现金	Other cash received related to investing activities		2,021,519.97
投资活动现金流入小计	Sub-total of cash inflows from investing activities	2,058,063,660.24	2,330,957,463.52
购建固定资产、无形资产和其他长期资产支付的现金	Purchase of fixed assets, intangible assets, and other non-current assets	157,871,020.42	137,137,802.25
投资支付的现金	Cash paid for investments	1,872,948,242.74	2,222,719,443.38

合并现金流量表 (续)
Consolidated Statement of Cash Flows (Continued)

项目	Item	2025年第一季度 First quarter of 2025	2024年第一季度 First quarter of 2024
支付其他与投资活动有关的现金	Cash paid relating to other investing activities		
投资活动现金流出小计	Sub-total of cash outflows from investing activities	2,030,819,263.16	2,359,857,245.63
投资活动产生的现金流量净额	Net cash flows from investing activities	27,244,397.08	-28,899,782.11
三、筹资活动产生的现金流量：	III. Cash Flows from Financing Activities:		
收到其他与筹资相关的现金	Cash received from other financing activities		
筹资活动现金流入小计	Subtotal of cash inflows from financing activities		
支付其他与筹资活动有关的现金	Cash payments relating to other financing activities	75,214,479.70	951,940.65
筹资活动现金流出小计	Sub-total of cash outflows from financing activities	75,214,479.70	951,940.65
筹资活动产生的现金流量净额	Net cash flow from financing activities	-75,214,479.70	-951,940.65
四、汇率变动对现金及现金等价物的影响	IV. Effect of exchange rate changes on cash and cash equivalents	1,466,877.94	44,446.57
五、现金及现金等价物净增加额	V. Net increase in cash and cash equivalents	112,243,062.09	51,481,078.54
加：期初现金及现金等价物余额	Add: Cash and cash equivalents at beginning of period	260,055,136.76	286,438,980.59
六、期末现金及现金等价物余额	VI. Cash and cash equivalents at end of period	372,298,198.85	337,920,059.13

公司负责人：	甘忠如	主管会计工作负责人：	孙程	会计机构负责人：	周丽
Legal Representative:	Zhongru Gan	Chief Accountant:	Cheng Sun	Head of Accounting Department:	Li Zhou

特此公告

Hereby announced officially.

甘李药业股份有限公司董事会
The Board of Directors of Gan & Lee Pharmaceuticals.

2025年4月23日
April 23, 2025



SCIENCE EXCELLENCE

甘李药业有限公司

Gan & Lee Pharmaceuticals.

地址：北京市通州区潮县镇南凤西一路8号

Address: No. 8, Nanfeng West 1st Street, Huoxian, Tongzhou District, Beijing

网址：<http://www.ganlee.com>

Website: <https://www.ganlee.com.cn>

电话：+86 010-80593699

Tel: +86 010-80593699

邮编：101109

Post code : 101109